Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accumulated Expenses (2022 - 2025)

Axsome Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 40.03% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $8.7 million, down 40.03%, while the annual FY2025 figure was $8.7 million, 40.03% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $8.7 million at Axsome Therapeutics, down from $27.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $46.7 million in Q4 2023 and bottomed at $705583.0 in Q2 2022.
  • The 4-year median for Accumulated Expenses is $7.6 million (2023), against an average of $12.3 million.
  • The largest annual shift saw Accumulated Expenses plummeted 71.51% in 2023 before it soared 855.02% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $26.5 million in 2022, then soared by 75.98% to $46.7 million in 2023, then plummeted by 69.11% to $14.4 million in 2024, then plummeted by 40.03% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Accumulated Expenses are $8.7 million (Q4 2025), $27.8 million (Q3 2025), and $21.1 million (Q2 2025).